



Abbott

FY 2016 PERFORMANCE

FINANCIAL RESULTS

SALES WORLDWIDE¹

+4.8%

ON OPERATIONAL BASIS*

\$20.9B

SALES WORLDWIDE

BUSINESS SEGMENT SALES

DIAGNOSTICS²

\$4.8B

+5.5%

NUTRITION³

\$6.9B

+1.2%

MEDICAL DEVICES⁴

\$5.2B

+4.5%

BRANDED GENERIC PHARMACEUTICALS⁵

\$3.9B

+10.5%

SALES COMPARED TO FY 2015 ON OPERATIONAL BASIS*

BUSINESS HIGHLIGHTS

Abbott Acquires St. Jude Medical Creates a Premier Medical Device Business

STRONG & DIVERSE PORTFOLIO



VASCULAR CARE



STRUCTURAL HEART DISEASE



HEART FAILURE



CARDIAC RHYTHM MANAGEMENT



NEUROMODULATION

#1 OR 2 LEADERSHIP POSITIONS
across large and high-growth cardiovascular disease device markets

Raising the Bar on Innovation

2016 Key Product Launches



Alinity™ systems designed to be more efficient and provide quality results for clinical chemistry, immunoassay, blood screening and point of care



ABSORB™, THE WORLD'S FIRST BIORESORBABLE CORONARY STENT



THE FREESTYLE LIBRE PRO™, A REVOLUTIONARY PROFESSIONAL CONTINUOUS GLUCOSE MONITORING SYSTEM**

¹ Reported sales +2.2% ² Reported sales +3.6% ³ Reported sales (1.1)% ⁴ Reported sales +3.8% ⁵ Reported sales +3.7%

*Operational results are non-GAAP as they exclude the impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated January 25, 2017, available at www.abbottinvestor.com.

**Additional FreeStyle Libre Pro information can be found at www.freestylelibrepro.us

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2015, and St. Jude Medical's Annual Report on Form 10-K for the fiscal year ended Jan. 2, 2016, respectively, and under the heading "Risk Factors" in Abbott's Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, and St. Jude Medical's Quarterly Report on Form 10-Q for the fiscal quarter ended April 2, 2016, which are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.